Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Accounts Payables (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Accounts Payables for 7 consecutive years, with $17.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 28.73% to $17.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.7 million through Dec 2025, up 28.73% year-over-year, with the annual reading at $17.7 million for FY2025, 28.73% up from the prior year.
  • Accounts Payables hit $17.7 million in Q4 2025 for Harmony Biosciences Holdings, down from $26.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $28.3 million in Q2 2025 to a low of $1.0 million in Q4 2021.
  • Historically, Accounts Payables has averaged $11.4 million across 5 years, with a median of $8.5 million in 2022.
  • Biggest five-year swings in Accounts Payables: tumbled 60.84% in 2021 and later soared 368.3% in 2023.
  • Year by year, Accounts Payables stood at $1.0 million in 2021, then soared by 278.22% to $3.8 million in 2022, then skyrocketed by 368.3% to $17.7 million in 2023, then dropped by 22.48% to $13.7 million in 2024, then increased by 28.73% to $17.7 million in 2025.
  • Business Quant data shows Accounts Payables for HRMY at $17.7 million in Q4 2025, $26.3 million in Q3 2025, and $28.3 million in Q2 2025.